Clinuvel Pharmaceuticals Limited
CLVLY · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $95,018 | $88,178 | $78,321 | $65,722 |
| % Growth | 7.8% | 12.6% | 19.2% | – |
| Cost of Goods Sold | $15,880 | $7,733 | $27,732 | $19,105 |
| Gross Profit | $79,137 | $80,445 | $50,589 | $46,617 |
| % Margin | 83.3% | 91.2% | 64.6% | 70.9% |
| R&D Expenses | $0 | $0 | $1,268 | $1,233 |
| G&A Expenses | $26,854 | $1,743 | $1,323 | $1,147 |
| SG&A Expenses | $26,854 | $25,025 | $8,411 | $12,301 |
| Sales & Mktg Exp. | $0 | $23,282 | $7,088 | $11,154 |
| Other Operating Expenses | $6,550 | $0 | $0 | $0 |
| Operating Expenses | $33,404 | $30,091 | $9,680 | $13,534 |
| Operating Income | $45,733 | $48,006 | $40,910 | $33,083 |
| % Margin | 48.1% | 54.4% | 52.2% | 50.3% |
| Other Income/Exp. Net | $5,820 | $2,673 | $687 | -$1,767 |
| Pre-Tax Income | $51,553 | $50,679 | $45,579 | $34,321 |
| Tax Expense | $15,380 | $15,043 | $14,974 | $13,442 |
| Net Income | $36,173 | $35,636 | $30,605 | $20,878 |
| % Margin | 38.1% | 40.4% | 39.1% | 31.8% |
| EPS | 0.72 | 0.72 | 0.62 | 0.42 |
| % Growth | 0% | 16.1% | 47.6% | – |
| EPS Diluted | 0.72 | 0.7 | 0.59 | 0.4 |
| Weighted Avg Shares Out | 50,076 | 49,834 | 49,410 | 49,410 |
| Weighted Avg Shares Out Dil | 50,380 | 51,027 | 51,816 | 51,776 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,431 | $7,325 | $3,906 | $444 |
| Interest Expense | $4,463 | $4,454 | $3,193 | $2,274 |
| Depreciation & Amortization | $1,181 | $1,142 | $789 | $758 |
| EBITDA | $57,197 | $56,276 | $41,699 | $33,841 |
| % Margin | 60.2% | 63.8% | 53.2% | 51.5% |